Malformations Following Methimazole Exposure In Utero: An Open Issue

Silvio Ferraris; Mariella Valenzise; Margherita Lerone; Maria Teresa Divizia; Lucia Rosaia; Dario Blaid; Odette Nemelka; Giovanni Battista Ferrero; Margherita Silengol

doi:10.1002/bdra.10098

Malformations Following Methimazole Exposure In Utero: An Open Issue

Silvio Ferraris, Mariella Valenzise, Margherita Lerone, Maria Teresa Divizia, Lucia Rosaia, Dario Blaid, Odette Nemelka, Giovanni Battista Ferrero, Margherita Silengol

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: In hyperthyroidism-complicated pregnancies, medical therapy is necessary to reach an euthyroid condition, and propylthiouracil (PTU) or methimazole (MMI) are used. These drugs are equally effective, but may cause fetal and neonatal hypothyroidism because they freely cross the placenta. Although PTU has not been significantly associated with embryo-fetal anomalies, it has been suggested that MMI might be responsible for a specific embryopathy. CASE(S): Two cases of major congenital anomalies after MMI exposure during pregnancy are reported. CONCLUSIONS: PTU should be the drug of choice, and the use of MMI should be restricted to cases with allergic reactions, intolerance, or poor response to PTU.

Original language	English
Pages (from-to)	989-992
Number of pages	4
Journal	Birth Defects Research Part A - Clinical and Molecular Teratology
Volume	67
Issue number	12
DOIs	https://doi.org/10.1002/bdra.10098
Publication status	Published - Dec 2003

Keywords

Aplasia cutis
Methimazole embryopathy
Thyroid

ASJC Scopus subject areas

Developmental Biology

Access to Document

10.1002/bdra.10098

Cite this

@article{e90fc5db1c4a483ea262818e55be2e0e,

title = "Malformations Following Methimazole Exposure In Utero: An Open Issue",

abstract = "BACKGROUND: In hyperthyroidism-complicated pregnancies, medical therapy is necessary to reach an euthyroid condition, and propylthiouracil (PTU) or methimazole (MMI) are used. These drugs are equally effective, but may cause fetal and neonatal hypothyroidism because they freely cross the placenta. Although PTU has not been significantly associated with embryo-fetal anomalies, it has been suggested that MMI might be responsible for a specific embryopathy. CASE(S): Two cases of major congenital anomalies after MMI exposure during pregnancy are reported. CONCLUSIONS: PTU should be the drug of choice, and the use of MMI should be restricted to cases with allergic reactions, intolerance, or poor response to PTU.",

keywords = "Aplasia cutis, Methimazole embryopathy, Thyroid",

author = "Silvio Ferraris and Mariella Valenzise and Margherita Lerone and Divizia, {Maria Teresa} and Lucia Rosaia and Dario Blaid and Odette Nemelka and Ferrero, {Giovanni Battista} and Margherita Silengol",

year = "2003",

month = dec,

doi = "10.1002/bdra.10098",

language = "English",

volume = "67",

pages = "989--992",

journal = "Teratology",

issn = "1542-0752",

publisher = "Wiley-Liss Inc.",

number = "12",

}

TY - JOUR

T1 - Malformations Following Methimazole Exposure In Utero

T2 - An Open Issue

AU - Ferraris, Silvio

AU - Valenzise, Mariella

AU - Lerone, Margherita

AU - Divizia, Maria Teresa

AU - Rosaia, Lucia

AU - Blaid, Dario

AU - Nemelka, Odette

AU - Ferrero, Giovanni Battista

AU - Silengol, Margherita

PY - 2003/12

Y1 - 2003/12

N2 - BACKGROUND: In hyperthyroidism-complicated pregnancies, medical therapy is necessary to reach an euthyroid condition, and propylthiouracil (PTU) or methimazole (MMI) are used. These drugs are equally effective, but may cause fetal and neonatal hypothyroidism because they freely cross the placenta. Although PTU has not been significantly associated with embryo-fetal anomalies, it has been suggested that MMI might be responsible for a specific embryopathy. CASE(S): Two cases of major congenital anomalies after MMI exposure during pregnancy are reported. CONCLUSIONS: PTU should be the drug of choice, and the use of MMI should be restricted to cases with allergic reactions, intolerance, or poor response to PTU.

AB - BACKGROUND: In hyperthyroidism-complicated pregnancies, medical therapy is necessary to reach an euthyroid condition, and propylthiouracil (PTU) or methimazole (MMI) are used. These drugs are equally effective, but may cause fetal and neonatal hypothyroidism because they freely cross the placenta. Although PTU has not been significantly associated with embryo-fetal anomalies, it has been suggested that MMI might be responsible for a specific embryopathy. CASE(S): Two cases of major congenital anomalies after MMI exposure during pregnancy are reported. CONCLUSIONS: PTU should be the drug of choice, and the use of MMI should be restricted to cases with allergic reactions, intolerance, or poor response to PTU.

KW - Aplasia cutis

KW - Methimazole embryopathy

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=0347623326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347623326&partnerID=8YFLogxK

U2 - 10.1002/bdra.10098

DO - 10.1002/bdra.10098

M3 - Article

C2 - 14745920

AN - SCOPUS:0347623326

SN - 1542-0752

VL - 67

SP - 989

EP - 992

JO - Teratology

JF - Teratology

IS - 12

ER -

Malformations Following Methimazole Exposure In Utero: An Open Issue

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this